Sascha Kuerti

ORCID: 0000-0003-0829-6072
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Cervical Cancer and HPV Research
  • Endometrial and Cervical Cancer Treatments
  • Colorectal and Anal Carcinomas
  • Galectins and Cancer Biology
  • Endometriosis Research and Treatment
  • Genital Health and Disease
  • Kruppel-like factors research
  • Palliative Care and End-of-Life Issues
  • Wnt/β-catenin signaling in development and cancer
  • Cancer Immunotherapy and Biomarkers
  • Intraperitoneal and Appendiceal Malignancies
  • Renal Diseases and Glomerulopathies
  • Angiogenesis and VEGF in Cancer
  • Lymphatic System and Diseases
  • Ethics in Clinical Research
  • Sarcoma Diagnosis and Treatment
  • Cancer and Skin Lesions
  • Toxin Mechanisms and Immunotoxins
  • Childhood Cancer Survivors' Quality of Life
  • Lipid metabolism and disorders
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Cancer Risks and Factors

University Medical Center Hamburg-Eppendorf
2016-2023

Universität Hamburg
2015-2023

Klinik und Poliklinik für Neurologie
2016

Eppendorf (Belgium)
2015

Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for tumour spread of epithelial ovarian cancer (EOC), possibly determined by the intercellular connecting protein E-Cadherin (E-Cad) its fragments. Tumour tissue 105 advanced EOC patients was evaluated expression E-Cad, β-Catenin Calpain western blotting immunohistochemistry. Expression patterns were compared between tumours with solely intraperitoneal (pT3c, pN0; n=41) metastases (pT1a-3c, pN1; n=64)....

10.1038/bjc.2015.436 article EN cc-by-nc-sa British Journal of Cancer 2016-01-01

// Sascha Kuerti 1, * , Leticia Oliveira-Ferrer Karin Milde-Langosch 1 Barbara Schmalfeldt Karen Legler Linn Woelber Katharina Prieske Sven Mahner 2 and Fabian Trillsch Department of Gynaecology Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany Obstetrics Gynaecology, Munich, Munich 81377, These authors have contributed equally to this work Correspondence to: Trillsch, email: Fabian.Trillsch@med.uni-muenchen.de Keywords: ovarian cancer, (VEGF)-A, -C,...

10.18632/oncotarget.17978 article EN Oncotarget 2017-05-18

In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might enable the development tailored therapy regimens. Moreover, no reliable for response to anti-angiogenic treatment with bevacizumab yet established. Angiopoietin-2 (Ang-2) an angiogenic growth factor, in lymphatic activation associated tumor progression. Here, we assessed potential Ang-2 as a marker...

10.1007/s00432-023-05354-1 article EN cc-by Journal of Cancer Research and Clinical Oncology 2023-09-08

Superficially invasive stage IA squamous vulvar cancer (VSCC) is defined as a single lesion measuring ≤2 cm with depth of invasion ≤1.0 mm (FIGO IA). This article examines the natural course and prognosis superficially VSCC.This retrospective case series 46 patients (median age 58 years) VSCC receiving wide local excision between January 1996 November 2014 in University Medical Center Hamburg-Eppendorf.Median tumor size was 4 mm. In 39/46 (84.8%) peri-tumoral high-grade intraepithelial...

10.1136/ijgc-2018-000046 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2019-01-13

At present, maintenance therapy with the antiangiogenic agent bevacizumab or PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response different therapies remains a major challenge. In present study we analyzed predictive potential vascular endothelial growth factor C (VEGF-C) identify patients that might benefit from an therapy.101 primary epithelial were...

10.1371/journal.pone.0269680 article EN cc-by PLoS ONE 2022-06-10

The value of pelvic lymphadenectomy (LAE) has been subject discussions since the 1980s. This is mainly due to fact that relation between lymph node involvement groin and pelvis poorly understood therewith need for treatment in general.N = 514 patients with primary vulvar squamous cell cancer (VSCC) FIGO stage ≥ IB were treated at University Medical Center Hamburg-Eppendorf 1996 2018. In this analysis, LAE (n 21) analyzed regard prognosis involvement.The majority had T1b/T2 tumors 15, 78.9%)...

10.1007/s00404-021-06156-x article EN cc-by Archives of Gynecology and Obstetrics 2021-08-13

Peritoneale Tumorzelldisseminierung und retroperitonealer Lymphknoten-Befall sind die Hauptausbreitungswege des epithelialen Ovarialkarzinoms (EOC). Die Regulationsmechanismen hierfür bisher noch nicht verstanden, möglicherweise kann dem interzellulären Verbindungsprotein E-Cadherin (E-Cad) seinen Fragmenten eine funktionale Rolle zugeschrieben werden.

10.1055/s-0036-1580668 article DE Geburtshilfe und Frauenheilkunde 2016-04-26

<h3>Background</h3> The value of pelvic lymphadenectomy (LAE) has been a subject discussion since the early 1980s. This is mainly due to fact that relation between lymph-node involvement groin and pelvis poorly understood therewith need for treatment in general. <h3>Patients Methods</h3> N=531 patients with primary vulvar squamous-cell cancer (VSCC) FIGO stage ≥ 1B were treated at University Medical Center Hamburg – Eppendorf (UKE)between 1996–2018. In this analysis only LAE (n=21) analyzed...

10.1136/ijgc-2020-igcs.129 article EN The Poster 2020-11-01
Coming Soon ...